Infratil Says CDC Data Centres Valuation Rises by A$448 Million
By David Winning
SYDNEY--New Zealand investment company Infratil said the value of its roughly 48% stake in the CDC Data Centres business has risen by 13% over the past six months.
Infratil said CDC is now worth between 3.641 billion Australian dollars (US$2.32 billion) and A$4.186 billion, representing a valuation gain of A$448 million through the end of March.
"CDC's data center design, operating model and customer base is strategically positioned to benefit from the new growth in demand for artificial intelligence services," said Chief Executive Jason Boyes. "These market dynamics have seen a significant uptick in inbound customer interest."
CDC is expecting a significant acceleration of construction and expansion of development planning in Canberra, Sydney, Melbourne and Auckland, he said.
CDC's net debt totaled A$2.27 billion at the end of September. Infratil said CDC continues to expect earnings before interest, tax, depreciation, amortization and financial derivative movements of between A$260 million and A$270 million in the 2024 fiscal year.
Write to David Winning at david.winning@wsj.com
(END) Dow Jones Newswires
October 08, 2023 16:04 ET (20:04 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?
-
A Cheap Dividend Aristocrat to Buy Before It Bounces Back
-
Alibaba Earnings: More Positive Outlook Despite Mixed Results
-
After Earnings and a 56% Rally In 2024, Is Arm Stock a Buy, a Sell, or Fairly Valued?
-
How Morningstar Rates Stocks